Your browser doesn't support javascript.
loading
Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer.
Canelo-Aybar, Carlos; Ferreira, Diogenes S; Ballesteros, Mónica; Posso, Margarita; Montero, Nadia; Solà, Ivan; Saz-Parkinson, Zuleika; Lerda, Donata; Rossi, Paolo G; Duffy, Stephen W; Follmann, Markus; Gräwingholt, Axel; Alonso-Coello, Pablo.
Afiliação
  • Canelo-Aybar C; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
  • Ferreira DS; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Ballesteros M; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Posso M; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
  • Montero N; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Solà I; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Saz-Parkinson Z; Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Lerda D; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Rossi PG; Department of Clinical Epidemiology and Public Health, Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Duffy SW; European Commission, Joint Research Centre (JRC), Ispra, VA, Italy.
  • Follmann M; European Commission, Joint Research Centre (JRC), Ispra, VA, Italy.
  • Gräwingholt A; Epidemiology Unit, AUSL - IRCCS di Reggio Emilia, RE, Italy.
  • Alonso-Coello P; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
J Med Screen ; 28(4): 389-404, 2021 12.
Article em En | MEDLINE | ID: mdl-33632023
ABSTRACT

OBJECTIVES:

Mammography screening is generally accepted in women aged 50-69, but the balance between benefits and harms remains controversial in other age groups. This study systematically reviews these effects to inform the European Breast Cancer Guidelines.

METHODS:

We searched PubMed, EMBASE and Cochrane Library for randomised clinical trials (RCTs) or systematic reviews of observational studies in the absence of RCTs comparing invitation to mammography screening to no invitation in women at average breast cancer (BC) risk. We extracted data for mortality, BC stage, mastectomy rate, chemotherapy provision, overdiagnosis and false-positive-related adverse effects. We performed a pooled analysis of relative risks, applying an inverse-variance random-effects model for three age groups (<50, 50-69 and 70-74). GRADE (Grading of Recommendations Assessment, Development and Evaluation) was used to assess the certainty of evidence.

RESULTS:

We identified 10 RCTs including 616,641 women aged 38-75. Mammography reduced BC mortality in women aged 50-69 (relative risk (RR) 0.77, 95%CI (confidence interval) 0.66-0.90, high certainty) and 70-74 (RR 0.77, 95%CI 0.54-1.09, high certainty), with smaller reductions in under 50s (RR 0.88, 95%CI 0.76-1.02, moderate certainty). Mammography reduced stage IIA+ in women 50-69 (RR 0.80, 95%CI 0.64-1.00, very low certainty) but resulted in an overdiagnosis probability of 23% (95%CI 18-27%) and 17% (95%CI 15-20%) in under 50s and 50-69, respectively (moderate certainty). Mammography was associated with 2.9% increased risk of invasive procedures with benign outcomes (low certainty).

CONCLUSIONS:

For women 50-69, high certainty evidence that mammography screening reduces BC mortality risk would support policymakers formulating strong recommendations. In other age groups, where the net balance of effects is less clear, conditional recommendations will be more likely, together with shared decision-making.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Detecção Precoce de Câncer Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: J Med Screen Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Detecção Precoce de Câncer Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: J Med Screen Ano de publicação: 2021 Tipo de documento: Article